MRK Stock: Unusual Put Activity Flags Downside Hedging as Merck Trades Near 52-Week Highs

By TrendSpider Editor

Merck & Company, Inc. is drawing attention today after two notable put contracts surfaced with a combined total premium of $1,295,000, suggesting institutional players may be hedging against downside risk. MRK currently trades at $119.935, up just 0.10% on the session, and sits close to its 52-week

MRK Stock: Unusual Put Activity Flags Downside Hedging as Merck Trades Near 52-Week Highs

Merck & Company, Inc. is drawing attention today after two notable put contracts surfaced with a combined total premium of $1,295,000, suggesting institutional players may be hedging against downside risk. MRK currently trades at $119.935, up just 0.10% on the session, and sits close to its 52-week high of $125.14. That context makes the bearish options positioning worth watching, especially given how far the stock has recovered from its 52-week low of $73.31.

Key Drivers of the MRK Stock Move

• Main Catalyst: Two unusual put contracts were flagged today, totaling $1,295,000 in premium. The larger of the two is a PUT at the $115 strike expiring January 21, 2028, with a size of 600 contracts, an open interest ratio of 5,000%, and a premium of $915,000. The second is a PUT at the $100 strike expiring September 18, 2026, with a size of 1,000 contracts, an open interest ratio of 43%, and a premium of $380,000.
• Bull Case: MRK is trading at $119.935, only about $5 away from its 52-week high of $125.14, reflecting underlying strength in the stock. The put activity could represent simple portfolio hedging by large holders looking to protect gains rather than an outright bearish directional bet. The $115 strike on the longer-dated contract still implies the buyer sees value in the stock holding above that level through early 2028.
• Bear Case: The $100 strike put expiring in September 2026 is deeply out of the money relative to the current price of $119.935, yet still attracted $380,000 in premium. Combined with the $915,000 spent on the longer-dated $115 put, the total $1,295,000 in premium outlay signals that at least some market participants are pricing in the possibility of a meaningful decline from current levels. A drop to $100 would represent a move of more than 16% to the downside.

Looking ahead, the forward setup for MRK carries a mixture of opportunity and uncertainty. The stock has staged a substantial recovery from its 52-week low of $73.31, and continued momentum toward the $125.14 high would represent a full round-trip. However, the concentration of put premium in longer-dated contracts suggests some institutional participants are thinking beyond near-term price action and positioning for potential weakness over a multi-month to multi-year horizon. Investors will want to monitor whether follow-on options activity skews further toward protection or if call-side interest begins to build as a counterweight.

MRK Unusual Options Activity

• Type: PUT | Strike: $115 | Expiry: January 21, 2028 | Volume: 600 | Open Interest: 5,000% above average (OTM)
• Type: PUT | Strike: $100 | Expiry: September 18, 2026 | Volume: 1,000 | Open Interest: 43% (OTM)

Both contracts are out of the money relative to the current price of $119.935. The January 2028 contract carries the larger premium at $915,000 and posted a notably elevated open interest percentage of 5,000%, making it the standout signal of the two. Total unusual options premium across both contracts came in at $1,295,000 with no call-side activity flagged.

MRK Seasonality

March has historically been a transitional month for large-cap pharmaceutical names as investors digest full-year results and begin positioning around mid-year catalysts such as clinical data readouts and conference season. With MRK trading near the upper end of its 52-week range heading into spring, seasonal patterns could either reinforce the current bid or expose the stock to profit-taking as the quarter progresses.

MRK Relative Performance

MRK's 0.10% gain on the session is modest, but its position near $119.935 against a 52-week low of $73.31 reflects a recovery of more than 63% from the bottom. That kind of range-wide recovery places Merck among the stronger large-cap performers in the healthcare space over the trailing year. How MRK holds up relative to the broader sector as options hedging activity grows will be a key signal to watch in the sessions ahead.